Gary S. Guthart

Board

Since January 2010

Age

58 years

Education

Holds a B.S. in Engineering from the University of California, Berkeley, and an M.S. and Ph.D. in Engineering Science from the California Institute of Technology.

Tenure

Joined ISRG in April 1996 and has held roles including COO, President, and currently serves as CEO since January 2010.

Also at INTUITIVE SURGICAL

DJR

David J. Rosa

President

Bob DeSantis

EVP, Chief Strategy and Corporate Operations Officer

GHL

Gary H. Loeb

SVP, General Counsel, and Chief Compliance Officer

About

Dr. Guthart has built a distinguished career characterized by a strong foundation in engineering and innovation. He started his professional journey by contributing to the development of early computer-enhanced surgical technologies during his tenure with SRI International, which set the stage for a groundbreaking career in the med-tech industry.

At ISRG, his leadership has been pivotal in driving the evolution of robotic-assisted surgery. His forward-thinking vision and operational expertise helped propel the development and commercialization of transformative surgical systems, significantly impacting patient outcomes and advancing minimally invasive procedures.

Beyond his executive role, Dr. Guthart has demonstrated a commitment to shaping the broader biomedical landscape through influential board positions at major companies such as Illumina and Affymetrix. His multifaceted contributions underscore a career marked by both technical prowess and strategic leadership.

$ISRG Performance Under Gary S. Guthart

Past Roles

Organization	Role	Date Range	Details
Intuitive Surgical, Inc.	President	July 2007 - May 2023	Held concurrently with other roles until May 2023
Intuitive Surgical, Inc.	Chief Operating Officer	February 2006 - July 2007	Role ended upon promotion to President
Intuitive Surgical, Inc.	Core Team Member	April 1996 - February 2006	Part of the core team developing foundation technology for computer-enhanced surgery
SRI International (formerly Stanford Research Institute)	Core Team Member	N/A	Developed foundation technology for computer-enhanced surgery

External Roles

Organization	Role	Date Range	Details
Illumina, Inc.	Board of Directors	Since December 2017	N/A

Fixed Compensation

Data from FY 2023

Component Name	Amount	Payment Schedule	Additional Details
Base Salary	$980,000	Annual (as of April 1, 2023)	11.4% increase from prior year
All Other Compensation	$56,267	Annual	Includes various components (breakdown not detailed)

Performance Compensation

Data from FY 2023

Annual Performance-Based Cash Bonus

Metric	Threshold	Target	Maximum	Weight	Additional Details
Adjusted Operating Income (AOI)	$2.198B	$2.381B	$2.775B	50%	Defined as operating income excluding CIP expense, share-based comp., and other adjustments
Company Performance Goals	Confidential	Confidential	Confidential	50%	Categories: Support Our Customers, Innovation & Operational Excellence, Quality & Regulatory, Financial
CIP Funding Level	N/A	N/A	N/A	N/A	107.1% overall funding; with AOI at 106.5% and Goals at 107.6%
Bonus Opportunity	N/A	150% of Base Salary	187.5% of Base Salary	N/A	Target Bonus: $1,432,500, Maximum Bonus: $1,790,625

Equity Incentive Plan Awards

Component	Grant Date	Grant Date Fair Value	Grant Date Stock Price	Shares/Units	Vesting Schedule	Performance Metrics / Conditions
Performance Stock Units (PSUs)	Feb 28, 2023	$5,774,416<br>(Performance: $4,027,515; Market: $1,746,901)	$229.39	Target: 21,069<br>Threshold: 15,802<br>Max: 26,336	Vest on third anniversary (Feb 28, 2026), contingent on performance and continued service	Metrics: 2022-2024 Procedure Count Growth (33.3%), 2022-2025 Procedure Count Growth (33.3%), and Relative TSR (33.3%)
Restricted Stock Units (RSUs)	Feb 28, 2023	$2,416,394	$229.39	10,534 RSUs	Time-based vesting in 1/4 increments over four years	Not performance-based; vests solely over time
Stock Options	Feb 28 & Aug 10, 2023	Feb 28: $1,137,582<br>Aug 10: $1,304,482	Feb 28: $229.39<br>Aug 10: $304.67	15,801 options each grant	Likely multi-year vesting; initial tranche (e.g., 6/48ths vesting after 6 months)	Performance indirectly influenced by the overall equity mix; details integrated with PSU metrics